Alopecia Clinical Trial
Official title:
A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects With Hair Loss
Verified date | November 2020 |
Source | Energenesis Biomedical Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.
Status | Completed |
Enrollment | 67 |
Est. completion date | December 26, 2019 |
Est. primary completion date | November 29, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: 1. Female, aged at least 20 years old 2. With hair loss over 100 hairs/day 3. Willing to maintain the same hair style, color, shampoo and hair products used, and approximate hair length starting from signing ICF and throughout the study 4. The subject of childbearing potential must show a negative urine or serum pregnancy test at Screening Visit 5. Have signed the written informed consent form Exclusion Criteria: Any subject meeting any of the exclusion criteria will be excluded from study participation. 1. With alopecia areata or cicatricial alopecia 2. With other scalp or hair disorders 3. With prior hair transplant 4. Use wigs or hair weaves 5. Plan to use any other concomitant therapy to treat hair loss, regrowth or volume during the study 6. Have taken any topical or systemic prescription of OTC medications for treating hair loss, hair regrowth and/or hair volume 7. Have used medications known to cause hair thinning, such as Coumadin and anti-depressants/anti-psychotics 8. Have received chemotherapy/cytotoxic agents as well as radiation/laser/surgical therapy of the scalp 9. Have initiated or terminated the use of hormones for birth control or hormone replacement therapy within 6 months. Subject will also be excluded from the study if she plans to initiate or terminate the use of hormones for birth control or hormone replacement therapy during the study. 10. With known or suspected hypersensitivity any ingredients of study product and active control 11. Any hematologic abnormalities. 12. Any serum chemistry abnormalities. 13. Pregnant, lactating, or premenopausal with childbearing potential but not adopting at least one form of birth control. 14. Enrollment in any investigational drug trial 15. With any condition judged by the investigator that entering the trial may be detrimental to the subject |
Country | Name | City | State |
---|---|---|---|
Taiwan | Taipei Veterans General Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Energenesis Biomedical Co., Ltd. | A2 Healthcare Taiwan Corporation |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The amount of hair loss | Change of the amount of hair loss at Week 12 from baseline.(hair loss is defined as the collection of hairs after combing at the study site) | Week 12 | |
Secondary | The amount of hair loss at each post-treatment visit | Week 2, 4, 6, 8, 10 | ||
Secondary | The thickness and density of hair | Change of hair thickness and density measured by phototrichogram at each post-treatment visit | Week 2, 4, 6, 8, 10, 12 | |
Secondary | Investigator assessment at each post-treatment visit | The hair loss will be assessed by the investigator using Investigator Photographic Assessment Questionnaire (IPAQ).The change from Baseline in hair growth will be assessed using the following 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased. | Week 2, 4, 6, 8, 10, 12 | |
Secondary | The hair wash/shed hair count at each post-treatment visit | Subjects will collect hairs full day, including after combing and hair-washing. Subjects should turn in these hair collections at each visit. The results will be averaged weekly. | Week 2, 4, 6, 8, 10, 12 | |
Secondary | The subject satisfaction | Subject satisfaction evaluated by Women's Androgenic Alopecia Quality of Life Questionnaire (WAA-QOL) at each post-treatment visit from baseline. WAA-QOL is a sixteen-question questionnaire to evaluate subjects' quality of life influenced by hair loss. Each question will be assessed using the following 7-point scale: 0 = not at all, 1 = a little bit, 2 = somewhat, 3 = a good bit, 4 = quite a bit , 5 = very much, 6 = extremely. | Week 2, 4, 6, 8, 10, 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04953416 -
Fractional Non-ablative Laser for the Treatment of Hair Loss
|
N/A | |
Completed |
NCT01929330 -
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
|
Phase 1 | |
Recruiting |
NCT05213936 -
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
|
N/A | |
Completed |
NCT02919735 -
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
|
Phase 2 | |
Recruiting |
NCT02591823 -
Hair Fall in Patients on Low Dose Methotrexate
|
N/A | |
Enrolling by invitation |
NCT01651689 -
Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia
|
N/A | |
Completed |
NCT01189279 -
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
|
Phase 1 | |
Recruiting |
NCT01111981 -
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia
|
Phase 4 | |
Terminated |
NCT01385839 -
Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata
|
N/A | |
Active, not recruiting |
NCT03382184 -
Fractional Photothermolysis for Hair Follicle Induction
|
Early Phase 1 | |
Not yet recruiting |
NCT05544448 -
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
|
N/A | |
Completed |
NCT03689452 -
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
|
N/A | |
Completed |
NCT06409650 -
To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia
|
Phase 2 | |
Recruiting |
NCT00801086 -
Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
|
Phase 2 | |
Completed |
NCT06095739 -
Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002
|
N/A | |
Completed |
NCT05587699 -
The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
|
Phase 1 | |
Terminated |
NCT02935569 -
Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy
|
N/A | |
Not yet recruiting |
NCT01557491 -
Hair Regrowth After Bicoronal Incision
|
N/A | |
Completed |
NCT01590238 -
Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
|
Phase 3 | |
Completed |
NCT00515762 -
Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling
|
Phase 2 |